¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Clinical oral implants research."¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • objective structured clinical examination
    °´°ü±¸Á¶È­Áø·á½ÃÇè
  • structured clinical interview
    ±¸Á¶È­ÀÓ»ó¸éÁ¢
  • oral
    1. ÀÔ- 2. °æ±¸- 3. ±¸µÎ-, ±¸¼ú- 4. ÀÔ¾È, ±¸°­
  • oral administration
    °æ±¸Åõ¿©
  • oral angle
    ÀÔ²¿¸®
  • oral arch
    ÀÔõÀåȰ, ±¸°³±Ã
  • oral bacteriology
    ±¸°­¼¼±ÕÇÐ
  • oral bacterium
    ÀÔ¼Ó±Õ
  • oral candidiasis
    ÀÔ¾ÈÄ­µð´ÙÁõ, ±¸°­Ä­µð´ÙÁõ
  • oral cavity
    ÀÔ¾È, ±¸°­
  • oral character
    ±¸°­±â¼º°Ý
  • oral cholecystography
    °æ±¸¾µ°³(ÁÖ¸Ó´Ï)Á¶¿µ(¼ú), °æ±¸´ã³¶Á¶¿µ(¼ú)
  • oral contraception
    °æ±¸ÇÇÀÓ(¹ý)
  • oral contraceptive
    °æ±¸ÇÇÀÓÁ¦, ¸Ô´ÂÇÇÀÓÁ¦
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • clinical trial
    ÀÓ»ó½ÃÇè
  • clinical ward
    ÀÓ»óº´µ¿
  • clinical dementia rating scale
    ÀÓ»óÄ¡¸ÅÆò°¡Ã´µµ
  • clinical target volume
    ÀÓ»óÇ¥ÀûüÀû
  • controlled clinical study
    °ü¸®È­ÀÓ»ó½ÃÇè
  • good clinical practice
    ÀǾàǰÀÓ»ó½ÃÇè°ü¸®±âÁØ
  • structured clinical interview
    ±¸Á¶È­ÀÓ»ó¸éÁ¢
  • oral administration
    °æ±¸Åõ¿©
  • oral angle
    ÀÔ²¿¸®
  • oral arch
    (¢¡palatal arch) ÀÔõÀåȰ
  • oral hypoglycemic agent
    °æ±¸Ç÷´ç°­ÇÏÁ¦
  • oral bacteriology
    ±¸°­¼¼±ÕÇÐ
  • oral bacterium
    ÀÔ¼Ó±Õ
  • oral cavity
    ÀÔ¾È, ±¸°­
  • oral cholecystography
    °æ±¸¾µ°³Á¶¿µ¼ú, °æ±¸´ã³¶Á¶¿µ¼ú
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • clinical microbiology
    ÀÓ»ó¹Ì»ý¹°ÇÐ
  • clinical mycology
    ÀÓ»óÁø±ÕÇÐ
  • clinical neurophysiology
    ÀÓ»ó½Å°æ»ý¸®ÇÐ(ìúßÉãêÌèßæ×âùÊ)
  • clinical otosclerosis
    ¹ßÇö¼º À̰æÈ­Áõ
  • clinical pharmacology
    ÀÓ»ó¾à¸®ÇÐ.
  • clinical record
    ÀÓ»ó±â·Ï(¡­ÑÀÒÓ).
  • clinical root
    ÀÓ»óÄ¡¾Æ»Ñ¸®
  • clinical sign
    ÀÓ»ó¡ÈÄ.
  • clinical sign
    ÀÓ»óÀû ¡ÈÄ
  • clinical significance
    ÀÓ»óÀû Á߿伺(¡­ñìé©àõ)
  • clinical specimen
    Àӻ󰡰˹°, ÀÓ»ó°Ëü
  • clinical syndrome
    ÀÓ»ó(Àû) ÁõÈıº
  • clinical target volume, CTV
    ÀÓ»óÇ¥ÀûüÀû
  • clinical trial
    ÀÓ»ó½ÃÇè.
  • clinical trial
    ÀÓ»ó½ÃÇè
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
CIS carcinoma in situ; catheter-induced spasm; central inhibitory state; Chemical Information Service; c...
CM California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ...
CPS carbamoylphosphate synthetase; cardioplegic perfusion solution; centipoise; cervical pain syndrome; ...
DCP dicalcium phosphate; Diploma in Clinical Pathology; Diploma in Clinical Psychology; District Communi...
AFCR American Federation for Clinical Research
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EORTC European Organisation for Research on Treatment of Cancer
FH-RDC Family History Research Diagnostic Criteria
GPRD General Practice Research Database
HSR Health Services Research
ICMR Indian Council of Medical Research
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • maladaptive oral habit
    ¼øÀÀ ºÒ·®¼º ±¸°­ ½À°ü
  • naso- ÄÚ¿ÍÀÇ °ü°è¸¦ ³ªÅ¸³»´Â Á¢µÎ¾î.

    naso-oral

    ºñ ±¸°­ÀÇ
  • oral acute pseudomembranous candidiasis
    ¾Æ±¸Ã¢
  • oral alveolar mucosa
    ±¸°­ Ä¡Á¶ Á¡¸·
  • oral anticoagulant
    °æ±¸ Ç×ÀÀÇ÷ ¾à
  • oral aphthae
    ±¸³» ¾ÆÇÁŸÁõ
    ±¸°­ Á¡¸·¿¡ ³ªÅ¸³ª´Â Àû»ö, ȸ»öÀÇ ÀÛÀº ¹ÝÁ¡À̳ª ±Ë¾ç.
  • oral arch
    ÀÔ±Ã, ±¸°³±Ã
  • oral cancer
    ±¸°­ ¾Ï
    Àüü ¾Ï ¹ß»ý ºóµµ¿¡¼­ ¾à 3¡­4%¸¦ Â÷ÁöÇÏ´Â ±¸°­ ¾ÏÀº Çô, »´, Ä¡ÁÖÁ¶Á÷, ¶Ç´Â ±¸ÀεÎÀÇ ¾î´À ºÎÀ§¿¡µµ ħ¹üÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â ±¸°­ ³»ÀÇ ¹ß»ý À§Ä¡¿¡ µû¶ó ´Þ¶óÁö±â´Â ÇÏÁö¸¸ ´ë°³ ¿©ÀÚº¸´Ù´Â ³²ÀÚ¿¡°Ô¼­ ¾à 2~6¹è ¸¹ÀÌ ¹ß»ýÇÏ¸ç ¿ì¸® ³ª¶ó¿¡¼­´Â 1³â¿¡ ¾à õ ¸í ³»Áö ÀÌ Ãµ¸íÀÇ »õ·Î¿î ±¸°­ ¾Ï ȯÀÚ°¡ ¹ß»ýÇϱ⠶§¹®¿¡ ±¸°­ ¾ÏÀ¸·Î Åõº´ ÁßÀΠȯÀÚ¸¸µµ ¼ö ¸¸ ¸í¿¡ À̸¥´Ù. 1996³â¿¡ ½ÃÇàÇÑ ÈÄÇ⼺ ¿¬±¸¿¡ ÀÇÇϸé Àüü ±¸°­ ¾Ï ȯÀÚÀÇ Æò±Õ 5³â »ýÁ¸À²Àº ¾à 46%·Î ¹Ý ÀÌ»óÀÇ È¯ÀÚ°¡ 5³â À̳»¿¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î Á¶»çµÈ¹Ù ÀÖ´Ù. ±¸°­ ¾ÏÀÇ À¯º´·üÀº ¿¬·É Áõ°¡¿Í °ü·ÃÀÌ ÀÖ´Ù. 40¼¼ ÀÌÈÄ¿¡ ¹ß»ý·üÀÌ ±ØÀûÀ¸·Î Áõ°¡Çϱ⠽ÃÀÛÇÏ¿© 60¼¼ÀÇ ¿¬·É¿¡¼­ ÀÏÁ¤ÇÑ À¯Áö °î¼±À» Çü¼ºÇÑ´Ù. ¾î¶² ¿ä¼Ò°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Å« ¿µÇâÀ» ³¢Ä¡´Â°¡¿¡ ´ëÇÑ ¹®Çå ¿¬±¸¿¡¼­ ´ã¹è¿Í ¼úÀÌ ¸ðµç ±¸°­ ¾ÏÀÇ 75%¸¦ ¾ß±âÇØ ÀÌ Áúȯ¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. Èí¿¬°ú °úÀ½ÀÌ °¢°¢ ±¸°­ ¾ÏÀÇ À§Ç輺À» Áõ°¡½ÃŰ´Â ¹Ý¸é, ±×µéÀÇ »óÇÕÈ¿°ú´Â ±× ¸î ¹èÀÎ °ÍÀ¸·Î ³ªÅ¸³ª¼­ °ñÃÊ¿¡ ¾ËÄÝ Áßµ¶À̶ó¸é Á¤»óÀÎÀÇ ¾à 30¹è ÀÌ»ó ÀÌȯÀ²ÀÌ ³ô¾ÆÁø´Ù. ±¸°­ ¾ÏÀÇ ÈçÇÑ Àü±¸ Áõ»óÀ¸·Î ¾Ë·ÁÁø ¹é¹ÝÁõÀº ±¸°­ Á¡¸·¿¡ Èò ¹éŸ¦ º¸ÀÌ´Â º´º¯À¸·Î ÀÌ ÁúȯÀÌ ¾ÏÁ¾À¸·Î ÁøÇàµÉ È®·üÀº 0.1%~36%ÀÇ ¸Å¿ì ´Ù¾çÇÑ ÆíÂ÷·Î º¸°íµÇ°í ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î´Â 10Áõ·Ê Áß 1Áõ·Ê°¡ ÀÌÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Àß ÀûÇÕµÇÁö ¾Ê´Â Ʋ´Ï³ª ¿À·¡ »ç¿ëÇÏ¿© ¸¶¸ðµÇ°í ³¯Ä«·Î¿öÁø ±Ý°ü µî¿¡ ÀÇÇÏ¿© Çù Á¡¸·À̳ª Çô, ¹«Ä¡¾Ç Ä¡Á¶Á¤ Á¡¸· µî¿¡ ¹ß»ýµÇ´Â ±Ë¾ç¼º º´º¯Àº Á¾±¹¿¡´Â ±¸°­ ¾ÏÀ¸·Î ÀüÀ̵DZ⠽¬¿î °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î ÁÖ±âÀûÀÎ Ä¡°ú °ËÁøÀÌ ÇÊ¿äÇÏ´Ù. ±¸°­ ¾ÏÀÇ À§Çè ¿ä¼Ò Áß¿¡´Â À¯ÀüÀû ¿ä¼Òµµ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÁ¤ Áý´Ü Áß¿¡´Â ¾ÏÀ» °¡Áö°í ÀÖ´Â °¡Á·ÀÌ ÀÖÀ¸¸é ±¸°­ ¾ÏÀÇ ¹ß»ý À§Ç輺ÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Èí¿¬°ú À½ÁÖ°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ Áß´ÜÇϰųª ÃÖ¼ÒÇÑ ÁÙÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. °Ç°­ÇÑ ½Ä»ýȰÀº ±¸°­ ¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ½Å¼±ÇÑ °úÀÏÀ̳ª ³ì»ö ä¼Ò´Â ±¸°­ ¾Ï ¹ß»ý·üÀ» °¨¼Ò½Ãų ¼ö ÀÖ°í, ÀÌ´Â ºñŸ¹Î A, C, E°¡ ÇÔÀ¯µÈ À½½ÄÀÌ ¿¹¹æ È¿°ú¸¦ °®´Â´Ù´Â »ç½ÇÀ» µÞ¹ÞħÇÑ´Ù. ±¸°­ Á¡¸·À» µ¥ÀÏ Á¤µµÀÇ ¶ß°Å¿î À½½ÄÀ̳ª ÀڱؼºÀÇ À½½ÄÀº ÇÇÇϵµ·Ï ÇÏ´Â °ÍÀÌ ÁÁ´Ù. HPVÀÇ ¹ßÇöÀ̳ª P53 À¯Àü ÀÎÀÚÀÇ º¯À§¿Í °°Àº ƯÁ¤ À¯ÀüÇÐÀû ¶Ç´Â Ãʱ⠼¼Æ÷ º¯È­°¡ ±¸°­ ¾Ï°ú °ü·ÃÀÌ ÀÖ´Ù´Â ¹ß°ßÀº ÃÖ±Ù ÁÖ¸ñ¹Þ°í ÀÖ´Â ¿¬±¸ÀÌ´Ù. °¡±î¿î ¹Ì·¡¿¡´Â ±¸°­ ¾ÏÀÇ À§Ç輺ÀÌ ³ôÀº ȯÀÚÀÇ ±¸°­ Á¡¸·À» ÁÖ±âÀûÀ¸·Î °Ë»çÇϰųª Ãʱ⠼¼Æ÷ º¯È­¸¦ º¸À̴ ȯÀÚ¸¦ ÀÎÁöÇÏ´Â °ÍÀÌ °¡´ÉÇÒ °ÍÀÌ´Ù. ±¸°­ ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ À§ÇÑ À¯¿ëÇÑ ±â¼úÀÇ °³¹ßÀº ÀÌ ºÐ¾ß¿¡¼­ ±â´ëµÈ´Ù. ±¸°­ ¾ÏÀº ¹ß»ý Ãʱ⿡´Â º°´Ù¸¥ Áõ»óÀ» º¸ÀÌÁö ¾Ê°í ¼­¼­È÷ ÁøÇàµÇ±â ¶§¹®¿¡ Á¶±â ¹ß°ßÀÌ ¹«Ã´ ¾î·Æ´Ù. ±¸°­ ¾Ç¾È¸é ¿µ¿ªÀÇ ¾ÏÀÇ Á¶±â ¹ß°ßÀº ¿©·¯ °¡Áö ÀÓ»óÀûÀÎ ¹ß°ßÀÌ ±âÃʰ¡ µÇ´Âµ¥ Ãʱ⿡´Â ´ë°³ ºÓÀº È«¹ÝÁõÀ» º¸À̸ç Á¡¸·ÀÌ °ÅÄ¥¾îÁö°í ¾à°£ À¶±âµÇ³ª À̶§´Â ¿°Áõ¼º º´¼Ò¿Í ºñ½ÁÇÏ¿© °¨º°ÀÌ °ï¶õÇÏ´Ù. ÀÌÈÄ ÁøÇàµÇ¾î ÀԾȿ¡ Èò ¸·ÀÌ »ý±â°Å³ª ÀÔ¾ÈÀÌ Çæ¾î ±Ë¾çÀÌ »ý±â°í º¸¸§ ÀÌ»ó ³´Áö ¾Ê°í Áö¼ÓµÇ´Â °æ¿ìµµ ÀÖ´Ù. ÀԾȿ¡ ¸¸¼ºÀûÀ¸·Î ¹é»ö º´¼Ò°¡ ÀÖ´Â °æ¿ì, ¸ñ¿¡ ¸Û¿ïÀÌ »ý±â°í ¾ø¾îÁöÁö ¾Ê´Â °æ¿ì ±¸°­ ¾ÏÀÌ ÀǽɵǹǷΠÁ» ´õ ¼¼¹ÐÇÑ Áø´ÜÀ» ¹Þ¾Æº¸´Â °ÍÀÌ ±ÇÀåµÇ¸ç Á¶±â Áø´Ü ½Ã »ýÁ¸À²Àº ÇöÀúÇÏ°Ô ³ô¾ÆÁö°Ô µÈ´Ù. ±¸°­ ¾Ï Ä¡·á ¹æ¹ýÀº ´ëÇ¥ÀûÀ¸·Î ¿Ü°úÀû ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç×¾Ï ¿ä¹ýÀ¸·Î ÀÌ·ç¾îÁö¸ç ´Üµ¶À¸·Î ¶Ç´Â º¹ÇÕÀûÀ¸·Î ½ÃÇàµÈ´Ù. ÃÖ±Ù¿¡ ¸é¿ª ¿ä¹ý, ±¤ ¿¡³ÊÁö ¿ä¹ý µîÀÌ °³¹ßµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÓ»óÀûÀ¸·Î Ȱ¹ßÈ÷ ÀÌ¿ëµÇ°í ÀÖÁö´Â ¸øÇÏ´Ù. ±¸°­ ¾Ç¾È¸é ºÎÀ§ÀÇ Á¾¾çÀÇ ÀýÁ¦ ½Ã¿¡´Â Åë»ó ¾Ç¾È¸é ºÎÀ§ÀÇ °á¼ÕÀ¸·Î ±â´É Àå¾Ö¿Í ¾È¸ð ÃßÇü µîÀÇ ½É¹ÌÀûÀÎ ¼Õ»ó°ú ÀÌ¿¡ µû¸¥ Á¤½Å ½É¸®Àû ¹®Á¦Á¡À» ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±¸°­ ¾Ï ÀýÁ¦¼ú ÈÄ ¾Ç°ñ ¹× ¿¬Á¶Á÷ °á¼ÕÀÌ ÀÖ´Â °æ¿ì¿¡ ¾Ç°ñ Àç°ÇÀ» ´Ü¼øÈ÷ º¹¿øÀ̶ó´Â °³³äÀ» ¶°³ª ½É¹ÌÀûÀ̰í ÀúÀÛ ±â´ÉÀÇ È¸º¹À̶ó´Â Â÷¿ø¿¡¼­ Àç°ÇÇÏ¿© »çȸÀûÀ¸·Î º¹±ÍÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
  • oral cavity
    ±¸°­
    ±¸°­Àº ÀÎü »ý¸í Çö»óÀ» À¯ÁöÇϱâ À§ÇÏ¿© À½½Ä¹°À» ¼·ÃëÇÏ´Â º»´ÉÀûÀÎ ÀúÀÛ ±â´ÉÀ» ÇÏ°í ¿¬ÇϽÃŰ¸ç ¹ßÀ½ ±â´ÉÀ» µµ¸ðÇÏ´Â ¼ÒÈ­±â °èÅëÀÇ Ã¹ °ü¹®ÀÌ´Ù. Á¦ÀÏ ¾Õ¿¡´Â ÀÔ¼ú°ú Ä¡¿­, »óºÎ¿¡´Â ±¸°³·Î ºñ°­°ú °æ°è¸¦ ÀÌ·ç¸ç Ãø¹æÀ¸·Î´Â ÇùºÎ·Î ¸·¾ÆÁø´Ù. ¶ÇÇÑ ÇϹ濡´Â Çô¿Í ¿¬Á¶Á÷ÀÌ ±¸°­Àú¸¦ ÀÌ·é´Ù. ÈĹæÀ¸·Î ¸ñÁ¥ ¹× Àεµ¿Í À̾îÁö¸ç ÈÄÃø¹æÀ¸·Î´Â Æíµµ¼±ÀÌ ÀÖ´Ù. ÇÑ ¸¶µð·Î ±¸°­Àº Àΰ£ÀÇ ¿©·¯ ±âÁö ¿å±¸¸¦ ÃæÁ·½ÃŰ´Â ±â°üÀÌ¸ç ¹°¸®Àû, ±â°èÀû, È­ÇÐÀû °¡±ØÀ» °¡Àå ½ÉÇÏ°Ô ¹Þ´Â ±â°üÀÌ´Ù.
  • oral character
    ±¸°­±â ¼º°Ý, ±¸¾Ö¼º ¼º°Ý
  • oral commissure
    ±¸°­ ±³·Ã
  • oral contraceptive
    °æ±¸¿ë ÇÇÀÓÁ¦
  • oral deformity
    ±¸°­ º¯Çü
  • oral diagnosis
    ±¸°­ Áø´Ü
  • oral diaphragm
    ±¸Àú Ⱦ°Ý¸·
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
epidemiologic research design The form and structure of analytic studies in epidemiologic and clinical research.
(12 Dec 1998)
united states agency for health care policy and research An agency of the public health service established in 1990 to "provide indexing, abstracting, translating, publishing, and other services leading to a more effective and timely dissemination of information on research, demonstration projects, and evaluations with respect to health care to public and private entities and individuals engaged in the improvement of health care delivery.." it supersedes the national centre for health services research.
(12 Dec 1998)
united states office of research integrity An office of the united states public health service organised in june 1992 to promote research integrity and investigate misconduct in research supported by the public health service. It consolidates the office of scientific integrity of the national institutes of health and the office of scientific integrity review in the office of the assistant secretary for health. The ori is in the office of the assistant secretary for health and its director reports directly to the assistant secretary for health, department of health and human services. (ri newsletter, 1993 jan; 1(1):1)
(12 Dec 1998)
Addison's clinical planes A series of plane's used as landmarks in thoracoabdominal topography; the trunk is divided vertically by a median plane from the upper border of the manubrium of the sternum to the pubic symphysis, by a lateral plane drawn vertically on either side through a point half way between the anterior superior iliac spine and the median plane at the interspinal plane, and by an interspinal plane passing vertically through the anterior superior iliac spine on either side; transversely the trunk is divided by a transthoracic plane passing across the thorax 3.2 cm above the lower border of the body of the sternum, by a transpyloric plane midway between the jugular notch of the sternum and the pubic symphysis, corresponding to the disc between the first and second lumbar vertebrae, and by an intertubercular plane passing through the iliac tubercles and cutting usually the fifth lumbar vertebra; the plane's formed on these lines, and also on transverse plane's cutting the upper edge of the manubrium and the upper edge of the pubic symphysis, constitute the clinical plane's of Addison.
(05 Mar 2000)
pathology, clinical A subspecialty of pathology which deals with the laboratory analysis of specimens of human blood and other fluids.
(12 Dec 1998)
chemistry, clinical The specialty of analytical chemistry applied to assays of physiologically important substances found in blood, urine, tissues, and other biological fluids for the purpose of aiding the physician in making a diagnosis or following therapy.
(12 Dec 1998)
pharmacology, clinical The branch of pharmacology that deals directly with the effectiveness and safety of drugs in humans.
(12 Dec 1998)
phase I clinical trial <pharmacology> The earliest stage clinical trial for studying an experimental drug in humans. Phase I trials are generally comparatively small and are used to determine toxicity and maximum dose.
They provide an initial evaluation of a drug's safety and pharmacokinetics-how the drug is absorbed, what tissues it reaches and how long it takes to leave the body. Such studies also usually test various doses of the drug (dose-ranging) to obtain an indication of the appropriate dose to use in later studies.
The patients in these trials usually have advanced disease and have already received best available chemotherapy, therefore, seeing a repose is significant partially because this means there is a lack of cross-resistance between two anti-cancer drugs.
(31 Dec 1997)
phase II clinical trial <pharmacology> Usually focus on the activity of the new product as a single agent in a noncomparative, open study.
(31 Dec 1997)
phase III clinical trial <pharmacology> An advanced stage clinical trial that should conclusively show how well a drug works as compared to other treatments.
Phase III trials are large, frequently multi-institution tests. They generally compare the relative value of the new drug compared with the current standard treatment and measure whether a new drug extends survival or otherwise improves the health of patients on treatment (clinical improvement) rather than just provide surrogate marker data. These studies generally last longer and are larger than phase II trials.
(31 Dec 1997)
Millon clinical multiaxial inventory A paper and pencil test, consisting of 20 clinical scales derived from 175 self-descriptive statements, and developed in 1977 for use in the assessment of psychopathology and the more enduring patterns of personality; specifically designed to correspond with some of the disorders of personality included in the Diagnostic and Statistical Manual of Mental Disorders used in diagnosis by mental health professionals.
Synonym: Millon clinical multiaxial inventory.
(05 Mar 2000)
Millon Clinical Multiaxial Inventory test A paper and pencil test, consisting of 20 clinical scales derived from 175 self-descriptive statements, and developed in 1977 for use in the assessment of psychopathology and the more enduring patterns of personality; specifically designed to correspond with some of the disorders of personality included in the Diagnostic and Statistical Manual of Mental Disorders used in diagnosis by mental health professionals.
Synonym: Millon clinical multiaxial inventory.
(05 Mar 2000)
clinical 1. Pertaining to a clinic or to the bedside.
2. Pertaining to or founded on actual observation and treatment of patients, as distinguished from theoretical or basis sciences.
(18 Nov 1997)
clinical anatomy The practical application of anatomical knowledge to diagnosis and treatment.
Synonym: applied anatomy.
(05 Mar 2000)
clinical burden A burden that differs from genetic burden mainly in the added component of morbidity; a trait that is neither a clinical or a genetic lethal may be grossly disabling.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á